Loading…
PROCEPT BioRobotics Corporation is projected to rise to $20.74 by 2027, a +11% move from its current price of $18.62. PRCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $18.03 | $18.63 | $19.26 | +0.08% |
| Aug 3 | $17.80 | $18.65 | $19.53 | +0.15% |
| Aug 4 | $17.63 | $18.66 | $19.75 | +0.23% |
| Aug 5 | $17.49 | $18.68 | $19.94 | +0.31% |
| Aug 6 | $17.37 | $18.69 | $20.11 | +0.38% |
| Aug 7 | $17.26 | $18.71 | $20.27 | +0.46% |
| Aug 8 | $17.16 | $18.72 | $20.42 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.16 | $18.72 | $20.42 | +0.54% |
| Week 2 | $16.65 | $18.82 | $21.28 | +1.07% |
| Week 3 | $16.28 | $18.92 | $21.99 | +1.61% |
| Week 4 | $15.99 | $19.02 | $22.63 | +2.16% |
| Week 5 | $15.75 | $19.12 | $23.22 | +2.71% |
| Week 6 | $15.54 | $19.23 | $23.78 | +3.25% |
| Week 7 | $15.36 | $19.33 | $24.32 | +3.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PROCEPT BioRobotics Corporation is a healthcare company focused on surgical robotics for urology, operating in the United States and internationally. It develops, manufactures, and sells robotic systems for minimally invasive urologic surgery, including AquaBeam Robotic System, an image-guided system aimed at treating benign prostatic hyperplasia. The HYDROS Robotic System provides Aquablation therapy image-guided robotic therapy to address lower urinary tract symptoms caused by BPH.
The company was incorporated in 2007 and is headquartered in San Jose, California. Its work centers on advancing robotic solutions to improve outcomes in urologic care and to enable image-guided surgical procedures for conditions like BPH.
PROCEPT BioRobotics Corporation (PRCT) operates in the Healthcare sector as a surgical robotics developer and seller focused on urology. The stock currently trades with a price of $17.70 and a market capitalization of $1.01B, and it holds a rank of 2445 among listed entities.
The 2026 price forecast shows a narrow range around the current level, with min $17.70, avg $17.70, and max $24.11, corresponding to a 0% ROI in that year. This suggests limited near-term upside relative to today, based on the provided projections.
Looking further ahead, the long-run forecast turns more bullish from 2032 onward, with 2032 avg $24.43 and max $39.45, 2033 avg $26.47 and max $43.64, and 2034 avg $27.70 with a max of $46.54. The 2040 and 2050 projections show substantial upside, with 2040 avg $37.36 and max $68.78 (ROI 111.1%), and 2050 avg $66.45 with a max of $135.94 (ROI 275.4%).
A major floor 31.2% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 26.0% above — a clean break opens room to run.
A major ceiling 56.2% above — clearing it would confirm fresh momentum.
Key PRCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.05 | Buy | $18.14 | Buy |
| MA 10 | $18.00 | Buy | $18.29 | Buy |
| MA 20 | $19.04 | Sell | $19.16 | Sell |
| MA 50 | $22.68 | Sell | $21.45 | Sell |
| MA 100 | $23.94 | Sell | $23.88 | Sell |
| MA 200 | $27.54 | Sell | $28.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.22 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -26.19 | Neutral |
| Williams %R (14) | -26.34 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | -2.77 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 73.66 | Neutral |
| TRIX (15) | -0.99 | Sell |
| Awesome (5,34) | -2.26 | Sell |
| Ultimate (7,14,28) | 51.47 | Neutral |
| Momentum (10) | -0.60 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 18.26 | Buy |
| ADX (14) | 26.35 | Sell |
| ATR (14) | 0.58 | Info |
The 30-day technical picture shows a bearish posture near-term, with RSI14 at 30. The stock trades below the SMA50 of $23.89 and the SMA200 of $28.12, indicating downside pressure.
Immediate support is listed at $17.70 and resistance at $29.09. The 30-day price range spans from $14.04 to $22.31, highlighting a recent pullback from mid-$20s toward the lower end of the range. Annualized volatility sits at 70%, underscoring elevated swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.69 | $18.62 | $25.26 | 0% | Neutral | |
| $16.24 | $20.74 | $28.18 | +11% | Neutral | |
| $15.64 | $20.69 | $29.38 | +11% | Neutral | |
| $15.55 | $21.17 | $31.10 | +14% | Neutral | |
| $14.42 | $20.13 | $30.42 | +8% | Neutral | |
| $15.49 | $22.14 | $34.29 | +19% | Neutral | |
| $17.98 | $26.26 | $41.59 | +41% | Bullish | |
| $18.77 | $27.99 | $45.21 | +50% | Bullish | |
| $19.74 | $30.01 | $49.37 | +61% | Bullish | |
| $17.64 | $27.33 | $45.72 | +47% | Bullish | |
| $24.08 | $40.65 | $72.96 | +118% | Bullish | |
| $37.40 | $73.53 | $146.05 | +295% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $16.69 | $18.62 | $22.75 | +0.00% |
| September 2026 | $15.95 | $18.98 | $23.32 | +1.96% |
| October 2026 | $16.63 | $19.96 | $24.83 | +5.15% |
| November 2026 | $16.93 | $20.45 | $25.70 | +2.47% |
| December 2026 | $16.39 | $19.92 | $25.26 | -2.62% |
Click any year to see its month-by-month PRCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PRCT could reach as high as $25.26, with a base case around $18.62 and support toward $16.69 — roughly 0% from $18.62. Price action looks broadly range-bound.
Expect PRCT to range from $16.24 to $28.18 through 2027. The $20.74 average target implies a +11% move from current prices. That is up +11% on the projected 2026 average. A consolidation phase looks the most probable path here.
The PRCT price prediction for 2028 points to an average of $20.69 (low $15.64, high $29.38) — a potential gain of +11% on today's $18.62. Price action looks broadly range-bound.
In 2029, PRCT is projected to trade between $15.55 and $31.10, averaging $21.17 — a potential gain of +14% from today's $18.62. That is up +2% on the projected 2028 average. A consolidation phase looks the most probable path here.
PROCEPT BioRobotics Corporation's 2030 outlook centres on $20.13, within a $14.42 to $30.42 range. That is -5% versus the projected 2029 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2031, PRCT could reach as high as $34.29, with a base case around $22.14 and support toward $15.49 — roughly +19% from $18.62. A consolidation phase looks the most probable path here.
Expect PRCT to range from $17.98 to $41.59 through 2032. The $26.26 average target implies a +41% move from current prices. That is up +19% on the projected 2031 average. Momentum favours further upside here.
The PRCT price prediction for 2033 points to an average of $27.99 (low $18.77, high $45.21) — a potential gain of +50% on today's $18.62. Buyers look set to stay in control over this stretch.
In 2034, PRCT is projected to trade between $19.74 and $49.37, averaging $30.01 — a potential gain of +61% from today's $18.62. That is up +7% on the projected 2033 average. Momentum favours further upside here.
PROCEPT BioRobotics Corporation's 2035 outlook centres on $27.33, within a $17.64 to $45.72 range. That is -9% versus the projected 2034 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PRCT could reach as high as $72.96, with a base case around $40.65 and support toward $24.08 — roughly +118% from $18.62. Momentum favours further upside here.
Expect PRCT to range from $37.40 to $146.05 through 2050. The $73.53 average target implies a +295% move from current prices. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRCT today (≈ 53.705693 PRCT) could be worth
$3,949.13
+$2,949.13 (+295%) by 2050 · US Dollar
Based on the average projected PRCT price of $73.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRCTwould be worth at today's price.
$1,000 invested in PRCT on Jul 31, 2025 (≈ 20.614307 PRCT) would be worth
$383.84
-$616.16 (-61.6%) today · 0.38× · US Dollar
Based on a PRCT entry price of $48.51 vs. today's $18.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.69 | $1,115.64 | +11.6% |
| 1 month ago | $23.47 | $793.35 | -20.7% |
| 3 months ago | $24.63 | $755.99 | -24.4% |
| 6 months ago | $29.14 | $638.98 | -36.1% |
| 1 year ago | $48.51 | $383.84 | -61.6% |
| All time (4.9y) ago | $41.94 | $443.97 | -55.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRCT forecast.
Our base-case forecast reaches $37.00 around 2040.
Implied market cap at $37.00: $2.11B
The multi-year forecast depicts a trajectory from 2026 through 2050 with varying upside. The 2030 forecast shows an average price of $18.96 with a 7.1% ROI, and bullish momentum becomes evident from 2032 with 2032–2035 showing rising averages and higher ROIs (2032 ROI 38%, 2033 ROI 49.5%, 2034 ROI 56.5%, 2035 ROI 41.3%).
The longer-horizon outlook strengthens further, with 2040 projecting an average of $37.36 and 111.1% ROI, and 2050 projecting an average of $66.45 with 275.4% ROI. Sentiment shifts to BULLISH from 2032 onward, reflecting a more favorable long-term path in the forecast. These are estimates, not guarantees, and actual results can differ due to market and company-specific developments.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $18.96 with a range from $13.37 to $29.16, yielding an estimated ROI of 7.1% and a NEUTRAL sentiment.
Yes. The forecast turns BULLISH starting in 2032, with 2032 average price $24.43 and ROI 38%, rising through 2033 (avg $26.47, ROI 49.5%) and into 2040 (avg $37.36, ROI 111.1%), culminating in 2050 (avg $66.45, ROI 275.4%).
The forecast for 2040 shows an ROI of 111.1% with an average price of $37.36 and a range up to $68.78.
The 2033 maximum forecast is $43.64, with an average of $26.47 and a minimum of $17.37, and a bullish outlook.
The current price is $17.70 and the market cap is $1.01B.
PROCEPT BioRobotics Corporation Community Discussion
0Share your PROCEPT BioRobotics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.